Couverture de Arnar Þór Jónsson: Hugsað upphátt

Arnar Þór Jónsson: Hugsað upphátt

Arnar Þór Jónsson: Hugsað upphátt

De : Arnar Þór Jónsson
Écouter gratuitement

3 mois pour 0,99 €/mois

Après 3 mois, 9.95 €/mois. Offre soumise à conditions.

À propos de ce contenu audio

 Vettvangur frjálsrar umræðu og gagnrýninnar hugsunar, frelsinu til varnarArnar Þór Jónsson Philosophie Sciences sociales
Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !
    Épisodes
    • Viðtal um stöðu lýðveldisins 2023

      Viðtal um stöðu lýðveldisins 2023
      Dec 27 2023

      Viðtal um stöðu lýðveldisins 2023.
      Afficher plus Afficher moins
      27 min
    • Ávarp á opnum fundi um sögu og sjálfstæði, frelsi og fullveldi

      Ávarp á opnum fundi um sögu og sjálfstæði, frelsi og fullveldi
      Dec 27 2023

      Ávarp á opnum fundi um sögu og sjálfstæði, frelsi og fullveldi.
      Afficher plus Afficher moins
      19 min
    • Sasha Latypova: An interview with Sasha Latypova in Reykjavik, Iceland

      Sasha Latypova: An interview with Sasha Latypova in Reykjavik, Iceland
      Nov 13 2023

      Alexandra 'Sasha' Latypova is a former pharmaceutical industry executive and entrepreneur. Latypova worked for 25 years in the pharmaceutical industry in various roles, and countries ultimately managing her own companies. She worked initially as an econometrics and management consultant, and later as a clinical trials contractor for 60+ pharma, large and small. Her clients included Pfizer, Johnson & Johnson, Novartis, AstraZeneca, GSK, and many smaller biotechnology companies.

      She worked with "channel partners" such as large contract research organizations (CROs) - Parexel, PPD, ICON, and others. She interacted with the FDA and other regulators on behalf of her clients and as a member of the Cardiovascular Safety Research Consortium on subjects related to assessments of cardiovascular safety of new drugs in clinical trials.
      Afficher plus Afficher moins
      1 h et 5 min
    Aucun commentaire pour le moment